Understanding Voting Rights and Shares Capital
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority, companies must disclose essential details about their shares and voting rights. This transparency is critical for stakeholders.
Current Market Information
Nanobiotix operates within significant market exchanges, specifically on Euronext Paris and the Nasdaq. Holding a presence in both markets allows the company to diversify its investor base and increase its visibility. Nanobiotix trades under the ticker symbol NBTX on Nasdaq and PARIS:NANO on Euronext.
Market Information Overview
Current listings emphasize the company's commitment to transparency and accessibility for its shareholders. The ISIN code for Nanobiotix is FR0011341205, and it features prominently on platforms like Bloomberg and Reuters to ensure broad public access to its stock performance.
Latest Voting Rights Data
As of the latest reporting period, the company has detailed its number of shares outstanding and its associated voting rights. For instance, the total number of shares outstanding was reported at 48,236,671, which accounted for significant voting rights across the board. Understanding these figures is essential for any prospective investors.
Total Voting Rights Comparison
Nanobiotix outlines theoretical and exercisable voting rights in its reports. The theoretical voting rights totaled 50,340,736 while exercisable voting rights reached 50,318,618. This differentiation helps shareholders understand the distinction between available voting power and actual voting rights, particularly in shareholder meetings.
About Nanobiotix
Nanobiotix is a pioneering late-stage clinical biotechnology company dedicated to revolutionizing treatment approaches through advanced physics-based therapies. Incorporated in 2003 and headquartered in Paris, it has established itself as a key player in biotech, listed on Euronext Paris since 2012 and on Nasdaq since December 2020.
Global Operations and Innovation
With subsidiaries in the United States, particularly in Cambridge, Massachusetts, Nanobiotix aims to widen its therapeutic impact globally. At the forefront of innovation, the company holds over 25 patent families across three distinct nanotechnology platforms, enhancing treatments in oncology and various other health disorders.
Commitment to Stakeholders
Nanobiotix is deeply invested in ensuring a nurturing environment not just for patients, but also for its investors and partners. Their mission extends beyond profits; it’s about making a meaningful difference in the healthcare landscape.
Contacting Nanobiotix
The company’s communication avenues include the Communications Department led by Brandon Owens, VP of Communications, and the Investor Relations Department guided by Joanne Choi for the US sector. Stakeholders or interested parties are encouraged to reach out to inquire about investments and corporate news.
Frequently Asked Questions
What is Nanobiotix's main business focus?
Nanobiotix focuses on developing innovative therapeutic agents, particularly using nanotechnology for cancer treatment and other medical applications.
How are voting rights calculated for Nanobiotix?
Voting rights are calculated based on the number of outstanding shares, with both theoretical and exercisable rights being reported in their disclosures.
Where is Nanobiotix listed?
Nanobiotix is listed on both Euronext Paris and the Nasdaq Global Select Market, which helps to broaden their investor reach and company visibility.
Who can potential investors contact for more information?
Potential investors can reach out to the Communications Department or the Investor Relations Department for inquiries and further information.
What innovations does Nanobiotix focus on?
Nanobiotix is focused on developing advanced treatments in oncology and improving bioavailability and biodistribution of drugs via its proprietary nanotechnology platforms.
